keyword
MENU ▼
Read by QxMD icon Read
search

Retinal vein occlusion

keyword
https://www.readbyqxmd.com/read/29756580/subtypes-of-antiphospholipid-antibodies-in-neurologic-accidents-an-observational-study
#1
Maryam Sahebari, Maryam Rastin, Reza Boostani, Mohsen Forughipour, Kamila Hashemzadeh, Samira HaajSadeghi
OBJECTIVE: Until now, concomitant neurological manifestations and positive antiphospholipid antibodies (APA(s)) have been investigated in different manners. The most important conflicts in this field are whether those manifestations are directly related to APA(s) or not and treatment strategies. METHOD: In this study, adopting a different manner, we selected patients with a recently defined neurological problem (according to study protocol) and positive APA without any other risk factor, to compare types, amounts, and titer of APAs...
May 14, 2018: Current Rheumatology Reviews
https://www.readbyqxmd.com/read/29746405/long-term-physical-stability-sterility-and-anti-vegf-bioactivity-of-repackaged-bevacizumab-in-2-ml-glass-vials
#2
Jan S Peterson, Kenneth Rockwell, Ingrid U Scott, Michael S Ip, Paul C VanVeldhuisen, Barbara A Blodi
PURPOSE: Repackaged bevacizumab in single-dose, prefilled syringes for intravitreal injection is available, but with shelf life limited from 60 days to 90 days. For the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2), 2-mL sterile glass vials were used rather than prefilled syringes to provide a longer shelf life for study supplies. METHODS: Repackaged bevacizumab in glass vials was tested at release and, for 1 lot, after 1, 3, 6, and 12 months for physical stability, including concentration, purity and appearance, and for sterility and endotoxins...
May 9, 2018: Retina
https://www.readbyqxmd.com/read/29744040/recent-advances-in-understanding-and-managing-retinal-vein-occlusions
#3
REVIEW
Daniel D Esmaili, David S Boyer
Retinal vein occlusions are the second most common form of retinal vascular disease. Previously, laser treatment for branch retinal vein occlusion and intravitreal triamcinolone acetonide for central retinal vein occlusion were the standard of care. Recent studies have demonstrated that anti-vascular endothelial growth factor (anti-VEGF) agents have a superior safety and efficacy profile for the treatment of both branch and central retinal vein occlusions. The use of wide-field fluorescein angiography has also allowed better visualization of the retinal periphery...
2018: F1000Research
https://www.readbyqxmd.com/read/29743025/risk-of-incident-atrial-fibrillation-in-patients-presenting-with-retinal-artery-or-vein-occlusion-a-nationwide-cohort-study
#4
Christine Benn Christiansen, Christian Torp-Pedersen, Jonas Bjerring Olesen, Gunnar Gislason, Morten Lamberts, Nicholas Carlson, Mathias Buron, Nikolai Juul, Gregory Y H Lip
BACKGROUND: The inter-relationships of atrial fibrillation (AF) to retinal vascular occlusions (whether retinal artery occlusion (RAO) or retinal venous occlusion (RVO)) remain unclear. It is unknown if a presentation of retinal artery or venous occlusions may indicate a new onset cardiac arrhythmia. To shed light on this association, we investigated the risk of new onset AF in patients with known RAO and RVO. METHODS: Patients with retinal occlusions from 1997 to 2011 were identified through Danish nationwide registries and matched 1:5 according to sex and age...
May 10, 2018: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/29719645/intravitreal-injection-of-anti-vascular-endothelial-growth-factor-agents-for-ocular-vascular-diseases-clinical-practice-guideline
#5
Homayoun Nikkhah, Saeed Karimi, Hamid Ahmadieh, Mohsen Azarmina, Majid Abrishami, Hossein Ahoor, Yousef Alizadeh, Hasan Behboudi, Narsis Daftarian, Mohammad Hossein Dehghan, Morteza Entezari, Fereydoun Farrahi, Heshmatollah Ghanbari, Khalil Ghasemi Falavarjani, Mohammad Ali Javadi, Reza Karkhaneh, Siamak Moradian, Masoud Reza Manaviat, Morsal Mehryar, Ramin Nourinia, Mohammad Mehdi Parvaresh, Alireza Ramezani, Alireza Ragati Haghi, Mohammad Riazi-Esfahani, Masoud Soheilian, Mohsen Shahsavari, Hossein-Ali Shahriari, Zhale Rajavi, Sare Safi, Armin Shirvani, Saeed Rahmani, Hamideh Sabbaghi, Mojgan Pakbin, Bahareh Kheiri, Hossein Ziaei
Purpose: To provide the clinical recommendations for the administration of intravitreal anti-vascular endothelial growth factor (VEGF) drugs especially bavacizumab for ocular vascular diseases including diabetic macular edema, neovascular age-related macular degeneration, myopic choroidal neovascularization, retinal vein occlusion and central serous chorioretinopathy. Methods: Twenty clinical questions were developed by the guideline technical committee. Relevant websites and databases were searched to find out the pertinent clinical practice guidelines to answer the questions...
April 2018: Journal of Ophthalmic & Vision Research
https://www.readbyqxmd.com/read/29708803/a-5-year-follow-up-study-of-the-treatment-of-macular-edema-due-to-retinal-vein-occlusion-using-dexamethasone-intravitreal-implants
#6
Gonzaga Garay-Aramburu, Ángela Gómez-Moreno
PURPOSE: To evaluate the long-term effects of intravitreal dexamethasone implants (IDIs) in eyes with macular edema (ME) due to retinal vein occlusion (RVO). METHODS: We reviewed the records of 10 patients followed for 5 years after they received their first IDI. The main outcome measures included changes in best corrected visual acuity (BCVA), central macular thickness (CMT), and central macular volume (CMV), and the incidence of side effects. RESULTS: Ten patients were included in the study with a mean follow-up of 65...
April 30, 2018: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29705175/ischemic-retinal-vein-occlusion-characterizing-the-more-severe-spectrum-of-retinal-vein-occlusion
#7
REVIEW
Meiaad Khayat, Michael Williams, Noemi Lois
Retinal vein occlusion (RVO), including central (CRVO), branch (BRVO) and hemicentral and hemispheric RVO, is the second most common vascular cause of visual loss, surpassed only by diabetic retinopathy. The presence and extent of retinal ischemia in RVO is associated with a worse prognosis. On this basis, most previously conducted studies considered iRVO and non-iRVO as separate entities based on set thresholds of existing retinal ischemia, as determined by fundus fluorescein angiography (FFA). Other diagnostic technologies have been used specifically in the differentiation of iCRVO and non-iCRVO...
April 26, 2018: Survey of Ophthalmology
https://www.readbyqxmd.com/read/29699979/changes-in-retinal-ischaemic-index-correlate-with-recalcitrant-macular-oedema-in-retinal-vein-occlusion-wave-study
#8
Soonil Kwon, Charles Clifton Wykoff, David M Brown, Jano van Hemert, Wenying Fan, SriniVas R Sadda
AIM: To evaluate changes in the ischaemic index (ISI) after targeted retinal photocoagulation (TRP) and to investigate the correlation between these changes and macular oedema (ME). METHOD: Twenty-four eyes of 24 patients with retinal vein occlusion (RVO) with recurrent ME were included. Ultra-widefield fluorescein angiography (UWFFA; Optos 200Tx) was obtained at baseline and every 4 months. The regions of retinal non-perfusion and the total gradable retina were manually segmented on UWFFA images for calculating the global ISI...
April 26, 2018: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/29696993/comparison-of-ranibizumab-and-subthreshold-micropulse-laser-in-treatment-of-macular-edema-secondary-to-branch-retinal-vein-occlusion
#9
Yelda Buyru Özkurt, Sezen Akkaya, Sibel Aksoy, Mert Hakan Şimşek
PURPOSE: To compare the effects of intravitreal ranibizumab injection and yellow (577 nm) subthreshold micropulse laser treatment in patients with macular edema following non-ischemic branch retinal vein occlusion. METHODS: The medical records of 51 patients who underwent intravitreal ranibizumab (0.5 mg) injection or subthreshold micropulse laser for the treatment of macular edema due to branch retinal vein occlusion were retrospectively reviewed. Subthreshold micropulse laser was administered with a 10% duty cycle, 100 μm spot diameter, 200 ms exposure time...
April 1, 2018: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/29689025/combination-therapy-of-intravitreal-ranibizumab-and-subthreshold-micropulse-photocoagulation-for-macular-edema-secondary-to-branch-retinal-vein-occlusion-6-month-result
#10
Hiroko Terashima, Hiruma Hasebe, Fumiki Okamoto, Naoki Matsuoka, Yayoi Sato, Takeo Fukuchi
PURPOSE: To determine the efficacy of the combination therapy of intravitreal ranibizumab (IVR) and 577-nm yellow laser subthreshold micropulse laser photocoagulation (SMLP) for macular edema secondary to branch retinal vein occlusion cystoid macular edema. METHODS: Retrospective, consecutive, case-control study. Forty-six eyes of 46 patients with treatment-naive branch retinal vein occlusion cystoid macular edema were enrolled. The IVR + SMLP group consisted of 22 patients who had undergone both SMLP and IVR...
April 23, 2018: Retina
https://www.readbyqxmd.com/read/29683983/fluorescein-angiography-indications-changes-after-optical-coherence-tomography-and-antiangiogenics
#11
Sonia C Labrador-Velandia, María R Sanabria
SIGNIFICANCE: The present study provides quantitative data regarding the change of indications of fluorescein angiography in a tertiary hospital. Exhaustively compiled data over more than 10 years concerning all the angiographic studies including diagnosis, first-visit/follow-up, possible relation with antiangiogenics approval, and optic coherence tomography (OCT) are presented. PURPOSE: The aim of this study was to determine the frequency and indications of fluorescein angiography before and after OCT and anti-vascular endothelial growth factor (anti-VEGF) treatment implantation...
April 20, 2018: Optometry and Vision Science: Official Publication of the American Academy of Optometry
https://www.readbyqxmd.com/read/29664983/longitudinal-quantification-of-retinal-nonperfusion-in-the-macula-of-eyes-with-retinal-vein-occlusion-receiving-anti-vegf-therapy-secondary-analysis-of-the-wave-randomized-trial
#12
William C Ou, Shaun I R Lampen, Charles C Wykoff
BACKGROUND AND OBJECTIVE: Longitudinal quantification of retinal nonperfusion (RNP) in eyes with retinal vein occlusion (RVO) undergoing anti-vascular endothelial growth factor therapy. PATIENTS AND METHODS: Thirty eyes with ischemic RVO were randomized to ranibizumab (Lucentis; Genentech, South San Francisco, CA) (monotherapy) or ranibizumab plus peripheral laser (combination therapy) in a 12-month, prospective trial. RNP on fluorescein angiography was quantified within the macula through 12 months of follow-up...
April 1, 2018: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/29663204/-acute-visual-loss-following-central-retinal-vein-occlusion
#13
REVIEW
Isabel Görsch, C Haritoglou
No abstract text is available yet for this article.
April 2018: MMW Fortschritte der Medizin
https://www.readbyqxmd.com/read/29662300/the-effects-of-repeated-ozurdex-injections-on-ocular-hypertension
#14
Sepehr Bahadorani, Chelsey Krambeer, Kendall Wannamaker, Wayne Tie, Michael Jansen, Jason Espitia, Jeong-Hyeon Sohn, Michael A Singer
Purpose: The purpose of this study was to correlate the degree of ocular hypertension with the number of Ozurdex injections. Methods: Intraocular pressure (IOP) fluctuations for a total of 183 injections were studied over a period of at least 12 months. The main indications for treatment were uveitis, diabetic macular edema, and retinal vein occlusion. Results: Results of the study demonstrate that repeated Ozurdex injections do not increase the frequency of IOP spikes beyond 30 mmHg...
2018: Clinical Ophthalmology
https://www.readbyqxmd.com/read/29662298/anti-vegf-treatment-of-macular-edema-associated-with-retinal-vein-occlusion-patterns-of-use-and-effectiveness-in-clinical-practice-echo-study-report-2
#15
J Michael Jumper, Pravin U Dugel, Sanford Chen, Kevin J Blinder, John G Walt
Purpose: To evaluate the efficacy, safety, and injection frequency of vascular endothelial growth factor (VEGF) antagonists in the treatment of macular edema secondary to retinal vein occlusion (RVO) in clinical practice. Patients and methods: A multicenter retrospective study of the medical records of 165 patients (95 branch RVO, 70 central RVO) treated with at least three anti-VEGF injections in the study eye was conducted. Available data collected for at least 6 months after the first injection included Snellen best-corrected visual acuity (BCVA), central retinal thickness (CRT) by time-domain optical coherence tomography (TD-OCT) or spectral-domain optical coherence tomography (SD-OCT), anti-VEGF injections, other treatments/procedures for RVO, and adverse events...
2018: Clinical Ophthalmology
https://www.readbyqxmd.com/read/29655642/estimating-medicare-and-patient-savings-from-the-use-of-bevacizumab-for-the-treatment-of-exudative-age-related-macular-degeneration
#16
Philip J Rosenfeld, Matthew A Windsor, William J Feuer, Sissi J J Sun, Kevin D Frick, Eric A Swanson, David Huang
PURPOSE: The Medicare cost savings from the use of bevacizumab in the United States for the treatment of exudative age-related macular degeneration (AMD) were estimated by replacing the use of bevacizumab with ranibizumab and aflibercept. DESIGN: Retrospective trend study. METHODS: Main outcome measures were spending by Medicare as tracked by Current Procedural Terminology (CPT) codes for intravitreal injections (67028) and treatment-specific J-codes (J0178, J2778, J9035, J3490 and J3590) for inhibitors of vascular endothelial growth factor...
April 12, 2018: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/29643797/uneventful-anterior-migration-of-intravitreal-ozurdex-implant-in-a-patient-with-iris-sutured-intraocular-lens-and-descemet-stripping-automated-endothelial-keratoplasty
#17
Andleeb Zafar, Ioannis M Aslanides, Vasileios Selimis, Konstantinos I Tsoulnaras, David Tabibian, George D Kymionis
Purpose: We report here the case of a patient with anterior segment migration of intravitreal dexamethasone implant as well as its management and outcome. Methods: The patient had the following sequence of events: complicated cataract surgery, iris-sutured intraocular lens implant, followed by cystoid macular edema treated with intravitreal Avastin, retinal vein occlusion treated with intravitreal dexamethasone implant, corneal decompensation treated with Descemet stripping automated endothelial keratoplasty (DSAEK), and finally recurrence of macular edema treated with repeated intravitreal dexamethasone implant...
January 2018: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/29629297/influences-of-pinpoint-plantar-long-wavelength-infrared-light-irradiation-stress-free-therapy-on-chorioretinal-hemodynamics-atherosclerosis-factors-and-vascular-endothelial-growth-factor
#18
Keisou Ishimaru, Takuma Nakajima, Yoshihisa Namiki, Kenji Ryotokuji
Background: We previously reported that pinpoint plantar long-wavelength infrared light irradiation (stress-free therapy; SFT) is useful for alleviating insulin resistance and improving intracranial blood flow in patients with type 2 diabetes mellitus. This study was undertaken to evaluate the influences of SFT on chorioretinal hemodynamics (retinal artery and vein blood flows) as well as atherosclerosis-related factors (TG, LDL-C) and VEGF in patients with dyslipidemia. Methods: Four patients with dyslipidemia received 15-minute irradiation with a stress-free apparatus (far-infrared wavelength, 30 mW)...
March 2018: Integrative Medicine Research
https://www.readbyqxmd.com/read/29624543/injection-frequency-of-aflibercept-versus-ranibizumab-in-a-treat-and-extend-regimen-for-central-retinal-vein-occlusion-a-randomized-clinical-trial
#19
Manuel Casselholm de Salles, Urban Amrén, Anders Kvanta, David L Epstein
PURPOSE: To prospectively investigate the injection frequency of aflibercept and ranibizumab in the treatment of macular edema in central retinal vein occlusion. METHODS: Patients with treatment-naive central retinal vein occlusion and macular edema were randomized to receive intravitreal injections with aflibercept (n = 22) or ranibizumab (n = 23) in a treat-and-extend regimen with a follow-up time of 18 months. After 3 loading doses, the treatment intervals were extended by 2 weeks to a maximum of 12 weeks...
April 5, 2018: Retina
https://www.readbyqxmd.com/read/29619262/optical-coherence-tomography-angiography-of-combined-central-retinal-artery-and-vein-occlusion
#20
Shuo-Chieh Wu, Victor M Villegas, Jaclyn L Kovach
Optical coherence tomography angiography (OCTA) is a new, noninvasive technology that enables detailed evaluation of flow in the retinal and choroidal vasculature. The authors believe this to be the first report to describe the optical coherence tomography angiography findings associated with combined central retinal artery occlusion (CRAO) and central retinal vein occlusion (CRVO).
2018: Case Reports in Ophthalmological Medicine
keyword
keyword
9749
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"